Oral ganciclovir for the prevention of CMV infection was the least cost-effective prophylaxis ($314000 per QALY saved). Results were most sensitive to the risk of developing an opportunistic infection, the impact of opportunistic infection history on long-term survival, and the cost of prophylaxis.
Jun 1, 1998 · The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients · Abstract · Volume 28, Issue 3 · Sign Up for INFORMS Publications ...
David Paltiel & Kenneth A. Freedberg, 1998. "The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients," Interfaces, INFORMS, vol. 28(3), ...
tained per-patient, cause-specific death costs from the AIDS Cost and Services Utilization ... 1996, "Cost-effectiveness of HIV screening in acute care settings," ...
People also ask
Is CMV related to AIDS?
Which drug is most suitable to treat cytomegalovirus CMV retinitis in patients with acquired immunodeficiency syndrome?
Cytomegalovirus (CMV) disease, an opportunistic complication in patients with AIDS, causes substantial morbidity and has high treatment costs.
We developed a computer-based, probabilistic simulation model of the natural history of HIV infection and AIDS in patients whose CD4 lymphocyte counts decline ...
We found that CMV prophylaxis confers additional quality-adjusted life-years at a lower-bound, marginal cost of $160,000. While this cost-effectiveness result ...
Cost-effectiveness analysis could potentially contribute by exploring thresholds of population risk, prophylactic effectiveness, and drug pricing in order to ...
Paltiel A, Freedberg K. The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients. Interfaces 1998, 28: 34-51. DOI: 10.1287/inte.28.3.34.
Preevaluation of Clinical Trial Data: The Case of Preemptive ...
academic.oup.com › cid › article-pdf
The previous anal-. Page 9. HIV/AIDS • CID 2001:32 (1 March) • 791 ysis produced less favorable results that we believe are attrib- utable to modeling ...